$18.96
−12.02%Nov 2, 2026, 12:30 UTC
The FDA placed Bright Minds Biosciences’ IND for BMB-101 in developmental and epileptic encephalopathies and related Protocol BMB-101-105 on partial clinical hold.
Source:Jul 31, 2026, 00:00 UTC
Vistagen Therapeutics appointed Douglas J. Williamson, M.D. as a director, effective July 29, 2026, with stock option compensation and eligibility for the Director Compensation Plan.